BTXA (lanbotulinumtoxinA) / Sinopharm - LARVOL DELTA

Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia (clinicaltrials.gov) - P2 | N=240 | Enrolling by invitation | Sponsor: LKGS_277

New P2 trial • Neuralgia • Pain

Effect of Botulinum Toxin Injection Guided by Ultrasound Combined With Balloon Localization on Cricopharyngeal Achalasia (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University

New trial • Gastrointestinal Disorder • Rare Diseases

Effect of Botulinum Toxin Injection Into Upper Esophageal Sphincter in Patients With Medullary Infarction (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University

New trial • Gastrointestinal Disorder

Ultrasound-assisted intravesical botulinum toxin A delivery attenuates acetic acid-induced bladder hyperactivity in rats. (PubMed, Front Pharmacol) - " Ultrasound-assisted intravesical delivery of BTX-A, with the assistance of MB cavitation, led to cleavage of SNAP-25, inhibition of calcitonin gene-related peptide release from afferent nerve terminals, and amelioration of acetic acid-induced bladder hyperactivity. These results support ultrasound-assisted intravesical delivery as an efficient non-injection method for administering BTX-A."

Journal • Preclinical • Overactive Bladder

The effect of calf subcutaneous fat thickness on patient satisfaction after calf contouring with botulinum toxin A. (PubMed, Plast Reconstr Surg) - "This study identified a U-shaped correlation between calf subcutaneous fat thickness and patient satisfaction rate after treatment. Our results provide a theoretical basis for BTXA treatment and suggest the importance of pre-procedure conversations in GM hypertrophy treatment."

Journal

Chinese botulinum toxin A for the treatment of lower urinary tract dysfunction: It works just as well. (PubMed, Bladder (San Franc)) - "While Botox (Allergan Inc., Irvine, CA) is currently being used across the globe, we have been using Chinese BoNT/A for many years for the treatment of DSD, NDO, idiopathic OAB, IC/BPS, BPH and UTI. Our experience showed that Chinese BoNT/A was as good as other BoNT/A products in terms of efficacy, safety, and tolerability. In this study, we explored the current and potential applications of Chinese BoNT/A in urology, and reviewed the background information regarding the toxin."

Journal • Review • Ataxia • Benign Prostatic Hyperplasia • Infectious Disease • Interstitial Cystitis • Movement Disorders • Muscle Spasticity • Musculoskeletal Pain • Nephrology • Overactive Bladder • Pain • Urology

A new paradigm of sewage collection in rural areas. (PubMed, Environ Sci Pollut Res Int) - "The q is used to create the best possible pipe network layout, determine the appropriate treatment method, and reduce construction costs. This model can be widely applied to sewage collection in rural areas of China, where the overall sewage collection system can implement different regional strategies to maximize rural pollution control and protect the environment."

Journal

Hengli Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. (PubMed, Front Pharmacol) - " Hengli BTX-A treatment was well-tolerated and resulted in significant improvements in OAB symptoms among Chinese patients inadequately managed by anticholinergics. Clinical Trial Registration: http://www.chinadrugtrials.org.cn/clinicaltrials.prosearch.dhtml, Identifier: CTR20131190."

Clinical • Journal • Infectious Disease • Nephrology • Overactive Bladder • Urinary Incontinence • Urology

"PetroChina, Hengli win four cargoes in first China oil reserve sale https://t.co/1wPq0yaIFb" (@Reuters)

Lantox-The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review. (PubMed, Toxins (Basel)) - "LAN seems to have a similar efficacy and safety features when compared to onabotulinumtoxinA using a 1:1 LAN- onabotulinumtoxinA conversion ratio. Large controlled multicentre studies will become necessary for LAN's registrations in Europe and North America."

Journal • Review • Gastroenterology • Ophthalmology • Pain • Pediatrics • Urology